This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult
participants with dyslipidemia who completed the blinded 12-month period from either parent
study and continue to meet eligibility criteria have the option to be enrolled into this
study. Eligible enrolled participants will initially receive open-label ARO-APOC3 at the dose
level assigned in the parent study until a final dose is selected, at which point all
participants will receive open-label ARO-APOC3 at the same dosing regimen.